Drug Profile

NTS 071

Alternative Names: NTS-071

Latest Information Update: 27 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NUTSHELL Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action Tumour suppressor protein p53 stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Solid tumours

Most Recent Events

27 Nov 2025 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) (PO), prior to November 2025 (NUTSHELL Therapeutics pipeline, November 2025) (NCT07060989)
04 May 2025 Nutshell Therapeutics plans a phase I trial for Solid tumours (Late-stage disease) in the USA and China (PO) (NCT07060989)
04 May 2025 US FDA approves IND application for NTS 071 in Solid tumours

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com